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Abstract 
Heroin dependence is associated with a stressful environment and with dysfunction of the 
hypothalamic-pituitary-adrenal (HPA) axis. The present study examined the acute effects of 
intravenous heroin versus placebo on the HPA axis response in heroin-dependent patients.  
Twenty-eight heroin-dependent patients in heroin-assisted treatment (HAT) and 20 age and gender 
matched healthy participants were included in a controlled trial in which patients were twice 
administered heroin or saline in a crossover design, and healthy controls were only administered 
saline. The HPA axis response was measured by adrenocorticotropic hormone (ACTH) levels and 
by cortisol levels in serum and saliva before and 20 min and 60 min after substance administration. 
Craving, withdrawal and anxiety levels were measured before and 60 min after substance 
application. Plasma concentrations of heroin and its main metabolites were assessed using high-
performance liquid chromatography. 
Heroin administration reduces craving, withdrawal and anxiety levels and leads to significant 
decreases in ACTH and cortisol concentrations (p<0.01). After heroin administration, cortisol 
concentrations did not differ from healthy controls, and ACTH levels were significantly lower 
(p<0.01). In contrast, when patients receive saline, all hormone levels were significantly higher in 
patients than in healthy controls (p<0.01).  
Heroin-dependent patients showed a normalized HPA axis response compared to healthy controls 
when they receive their regular heroin dose. These findings indicate that regular opioid 
administration protects addicts from stress and underscore the clinical significance of HAT for 
heroin-dependent patients. 
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Introduction  
Substance dependence is a chronic relapsing brain disorder that is characterized by an 
overwhelming compulsion to seek and use drugs, despite negative consequences (1). It is well 
known that substance dependence is marked by abnormal hypothalamic-pituitary-adrenal (HPA) 
axis function (2, 3). An atypical stress response occurs in both heroin and cocaine dependence (4-6).  
Whereas cocaine activates the HPA axis and thus elevates adrenocorticotropic hormone (ACTH) 
and cortisol levels (7), heroin and other opiates may suppress stress hormone secretion (8, 9). HPA 
axis activation has been observed during opioid withdrawal syndromes (10, 11).  
Stress and stress response are closely associated with drug use. Stress is known to increase drug 
craving, anxiety, ACTH and cortisol secretion and may be associated with further drug use (12-15).  
It has been argued that heroin-dependent patients suffer from persistent hyper-responsiveness to 
stress, even after detoxification, which reflects heightened sensitivity of the hypothalamus and the 
pituitary gland to negative emotional stimuli and consequently might contribute to later drug use 
(16).  
Maintenance treatment with methadone or buprenorphine is seen as the treatment of choice in 
heroin dependence (17). Alternative pharmacological strategies have been considered as treatment 
options, including the prescription of heroin (diacetylmorphine, DAM) itself. Heroin-assisted 
treatment (HAT) is now available in several countries and has given good outcomes (18).  
Regular opioid administration could damp the inadequate stress response of heroin-dependent 
patients and thus defend the individual from aversive experiences such as negative affects (19).  
There is empirical evidence that the altered HPA axis function in heroin dependence partially 
returns to normal during opioid maintenance treatment (20, 21). However, some abnormalities in 
the HPA axis response seem to persist even during stable opioid maintenance treatment (22, 23). 
This study examined the acute effects of heroin on the HPA axis response in heroin-dependent 
patients, in comparison to placebo and to healthy participants. For ethical reasons, healthy controls 
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were included for placebo administration only. We hypothesized that HPA axis activity would be 
reduced after heroin administration and that the HPA response in heroin-dependent patients would 
be normalized in comparison to healthy participants.  
 
Patients and methods 
Study sample 
Table 1 summarizes the socio-demographic and diagnostic characteristics of the study sample. 
Twenty eight heroin-dependent outpatients were recruited from the Division of Substance Use 
Disorders of the Psychiatric Hospital of the University of Basel (Switzerland). They were aged 23-
58 years (mean age = 41.3, SD = 6.6), met the DSM-IV diagnostic criteria for opioid dependence 
and had been in heroin-assisted treatment for 6.7 years on average (SD = 4.5). Their daily dose of 
prescribed heroin ranged from 30 mg to 700 mg per day.  
The inclusion criteria were: age older than 18 years, history of intravenous heroin dependence, 
having been on current stable heroin-assisted treatment for at least 6 months, and unchanged heroin 
dose during the previous 3 months. Exclusion criteria were a positive alcohol breathalyzer test and 
an additional physical disease or psychiatric disorder, including other comorbid substance 
dependence.  
In the heroin-assisted treatment regime, heroin is administered twice a day. The details of the 
heroin-assisted treatment program in Switzerland have been described elsewhere in more detail (24, 
25). 
When patients fulfilled the inclusion criteria, the history of heroin and other illicit substance use 
was assessed with the semi-structured interview according to ICD-10 research criteria. Patients 
were told to abstain from illicit drug use other than prescribed heroin for the duration of the study, 
from alcohol intake for 72 hours and from tobacco consumption for 2 hours before scanning. Before 
the experiment, the patients had had no opioid intake for about 10 hours. 
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The healthy controls were carefully screened using a semi-structured clinical interview to exclude 
psychiatric or physical illness or a family history of psychiatric illness. Participants who had ever 
used any other illicit psychotropic drug, who consumed more than 20 g alcohol per day, or who had 
any psychiatric, neurologic, or severe medical illness history, were also excluded. Healthy controls 
were recruited from the general population by advertisement in the same geographical area. After 
the study had been completely described to the subjects, written informed consent was obtained. 
The study was approved by the local ethics committee. 
 
[Please here Table 1] 
 
Study design 
The heroin-dependent patients were examined on two occasions one week apart, in a crossover 
design. The patients were randomly assigned following simple randomization procedures 
(computerized random numbers) to one of two injected substance (heroin vs. placebo = saline). One 
patient group (n = 14) received first heroin before the experiment, whereas the second patient group 
(n = 14) received first saline. One week later, they received the other substance before the 
experiment. All patients were informed that they received heroin or placebo before or after the 
experiment. The patients and the experimenter were blind to the administered substances. The 
healthy controls participated only in the placebo condition. The study has been registered by the 
website http://clinicaltrials.gov (ID NCT01174927). 
 
Study procedure 
The study procedure is shown in Table 2. At the start of the study day, a urine sample was collected 
for screening for amphetamines, benzodiazepines, cocaine, methamphetamine, morphine, and THC 
using immunometric assay kits. Alcohol use was tested with an alcohol breathalyzer test. 
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After completion of the baseline measurement, heroin-dependent patients received either their dose 
of prescribed heroin in 5 ml, or the same dose of saline, through an indwelling intravenous catheter 
over a period of 30 sec. Healthy controls were injected with 5 ml of saline over 30 sec. Heroin was 
provided by the Swiss Federal Office of Public Health in the form of the hydrochloride salt. It was 
dissolved in sterile water on site and aspirated into a syringe, adapted to the evacuated infusion 
system (26).  
Adrenocorticotropic hormone (ACTH) and cortisol were taken as measures of the HPA axis 
response. Samples were collected through an intravenous catheter at baseline, 20 min and 60 min 
after substance administration. The concentrations of heroin and its metabolites were obtained at 
baseline and 3 min, 10 min and 60 min after the patients had received their heroin injection. Self-
report measures were assessed before and 60 min after substance application. 
 
[Please here Table 2] 
 
Bioanalytical and biochemical measurements 
The concentrations of DAM and its metabolites were measured in venous ammonium-heparinized 
plasma obtained from 23 patients at baseline and 3 min, 10 min and 60 min after individualized 
heroin injection. Plasma levels of DAM, 6-acetylmorphine (6AM), morphine (M), morphine-3-β -
D-glucuronide (M3G), and morphine-6-β-D-glucuronide (M6G) were assessed using high-
performance liquid chromatography on a 125x2 mm i.d. Nucleosil 50 C-8 ec column with a particle 
size of 5 µm and a 8 x 3 mm i.d. precolumn packed with Nucleosil 120 C-8 and a particle size of 3 
µm, followed by diode-array detection. Sample preparation and instrumental conditions were as 
described previously in detail (27). Minor optimization steps included the adjustment of the sample 
pH to 8.0 for the solid-phase extraction, to prevent DAM hydrolysis, and the multi-step gradient 
applied during the chromatographic separation. 
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Salivary cortisol was analyzed with a time-resolved immunoassay with fluorescence detection, as 
described elsewhere (8). Total cortisol concentrations were measured in serum with the Immulite 
2000 Cortisol-Test (Siemens, Germany). The measurement range of the test is at 1 – 50 ug/dl; the 
analytical sensitivity is 0.20 ug/dl. The test shows an intraassay precision of 7.4% and an interassay 
precision of 9.4 %. The reference range of the concentration of cortisol depends on the time of day, 
with morning levels of 5 – 25 ug/dl. ACTH was measured in EDTA plasma with the ACTH 
Immulite-Test (Siemens, Germany). The intraassay precision was < 6.1% for concentrations > 50 
pg/ml; the interassay precision was 9.4% for concentrations > 51 pg/ml. The analytical sensitivity 
of this test is 9 pg/ml. The recovery range of this test is 91 – 107%. The median of a study with 59 
test persons in good health (male/female) performed by the manufacturer showed a value of 24 
pg/ml and a 95%-reference range of n.d. – 46 pg/ml. 
 
Interviews and self-report measures  
Clinically experienced psychiatrists conducted the Structured Clinical Interview for DSM-IV for 
DSM-IV Axis II Disorders (SCID-II) (28) to assess the diagnosis of a comorbid personality 
disorder. The Heroin Craving Questionnaire (HCQ) was assessed to measure perceived craving and 
withdrawal level (29, 30). The State-Trait Anxiety Inventory (STAI) was administered to examine 
the state anxiety (31).  
 
Statistical analyses 
Statistical analyses were conducted using SPSS for Windows (version 17.0). Primary endpoints 
were the cortisol and ACTH levels. 
A repeated-measures ANOVA was performed with the two within factors for substance (heroin vs. 
saline) and three time points (baseline, 20 min and 60 min after substance injection). The factor 
order of the substance was randomized between subjects. The random order of substance 
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administration, age, gender and personality disorder diagnosis were used as covariates. When 
within factors were significant, Tukey’s post-hoc tests were performed. To protect against 
violations of sphericity, repeated-measures data were adjusted for within-factor degrees of freedom, 
using the Greenhouse-Geisser correction where appropriate. 
The differences between heroin-dependent patients and healthy controls were tested with t-test for 
the three primary endpoints. Because of multiple comparisons, alpha was adjusted for 7 tests using 
the Bonferroni correction. As consequence, all statistical tests were considered significant at a two-
tailed level of p < 0.0072.  
 
Results 
Plasma concentrations of heroin and its metabolites  
Heroin (diacetylmorphine, DAM) peak plasma concentrations rose to 1005 ng/ml at 3 min after 
heroin administration, due to the extremely short plasma elimination half-life of the drug. At the last 
sampling time point, DAM (35 - 139 ng/ml) was still measurable in 3 patients. 6AM exhibited a 
similar time-concentration profile to that of DAM. M was detectable in all patients and at all 
sampling time points after administration of DAM, with a peak plasma concentration at 3 min (20 
patients) and 10 min (3 patients). The decline in the plasma concentrations of M was considerably 
slower than for DAM and 6AM, reflecting the much longer elimination half-life for M compared to 
the acetylated compounds. At  
3 min, 10 min and 60 min, the concentration ranges were 39 - 3885, 31 - 761, and 29 - 436 ng/ml, 
respectively. This indicates relatively stable plasma levels of M over a prolonged time period, with 
the highest inter-individual variability observed at 3 min. The M3G and M6G plasma 
concentrations steadily increased over the study period of 60 min, approaching a plateau at the end 
of the study. At the last sampling time point, the M3G concentrations were between 281 and 4432 
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ng/ml. Considerably lower concentrations were found for M6G, ranging between of 81 and 1099 
ng/ml. The plasma profiles of heroin and its metabolites are depicted in Figure 1. 
 
[Please here Figure 1] 
 
Effects of heroin on self-report measures  
After the application of heroin, perceived craving (t = 5.19, df = 27, p < 0.001) and withdrawal (t = 
4.42, df = 27, p < 0.001) decreased significantly. After saline injection, the withdrawal level 
increased significantly (t = -2.83, df = 27, p < 0.01) and craving scores did not change. The state 
anxiety decreased after heroin administration (t = 6.16, df = 27, p < 0.001), and did not change after 
saline. After heroin administration, patients did not differ from healthy controls in their self-report 
measures.  
 
Effects of heroin vs. saline in heroin-dependent patients 
The repeated-measures ANOVA showed a significant substance (heroin vs. saline) and time 
interaction for ACTH (F = 11.21, p = 0.001), serum cortisol (F = 45.59, p < 0.001) and saliva 
cortisol concentrations (F = 20.16, p < 0.001) in heroin-dependent patients (p < 0.001). Moreover, 
there were significant time effects for ACTH (F = 6.06, p = 0.014) and serum cortisol levels (F = 
16.46, p < 0.001).  
According to the post-hoc tests, ACTH decreased significantly from baseline to 20 min (F = 5.54, p 
< 0.05) and from 20 min to 60 min after heroin administration (F = 40.65, p < 0.0001). Serum 
cortisol (F = 51.50, p < 0.0001) and saliva cortisol (F = 12.99, p = 0.001) decreased from baseline 
to 20 min after heroin administration, and serum cortisol (F = 42.50, p < 0.0001) and saliva cortisol 
(F = 26.70, p < 0.0001) decreased again from 20 min to 60 min after heroin administration. We 
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included random order of substance administration, age, gender and personality disorder diagnosis 
as covariates in the ANOVA. There was no significant influence on stress hormone levels.  
 
Effects of heroin and saline in heroin-dependent patients vs. saline in healthy controls 
The differences in stress hormone levels between heroin-dependent patients and healthy controls 
during the experiment are shown in Figures 2-4. At baseline, ACTH concentrations were 
significantly higher in patients than in healthy controls (t = 2.96, df = 37.52, p = 0.005). Sixty min 
after substance administration, serum cortisol and salivary cortisol did not differ between heroin-
dependent patients and healthy controls when patients received heroin. ACTH concentrations were 
significantly lower 60 min after heroin administration in heroin-dependent-patients than in healthy 
controls (t = -3.55, df = 46, p = 0.001). When the heroin-dependent patients received saline, ACTH 
(t = 4.98, df = 29.97, p < 0.0001, serum cortisol (t = 3.87, df = 46, p < 0.0001), and salivary cortisol 
concentrations (t = 4.01, df = 43.17, p < 0.0001) were significantly higher than in healthy controls 
at the end of the experiment.  
 
[Please here Figure 2] 
 
[Please here Figure 3] 
 
[Please here Figure 4] 
 
Discussion 
This study examined the acute effects of heroin on the HPA axis response in heroin-dependent 
patients compared to placebo and to healthy controls. We found that all stress hormones decreased 
in heroin-dependent patients after heroin administration. Importantly, stress hormone levels did not 
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differ (cortisol) or were even lower (ACTH) than those in healthy controls when they received 
heroin. However, during saline treatment, the stress hormone levels were higher in patients than in 
healthy controls. This finding highlights the acute suppressive effect of heroin on the HPA axis. 
Moreover, it indicates that ─ even on stable opioid maintenance treatment ─ heroin-dependent 
patients still show a different HPA axis response than healthy persons when they do not receive 
their daily opioid dosage. We have found a higher HPA axis response in heroin-dependent patients 
after saline injection than in healthy control persons. This finding supports previous results showing 
partial normalized HPA axis activity in methadone-maintained heroin-dependent patients compared 
to active and former heroin users (16). It could be inferred that heroin-dependent patients in HAT 
need to inject their daily heroin dose to suppress their HPA axis activity.  
Before substance administration, hormone levels (ACTH) were elevated in patients compared to 
controls. This probably reflects the beginnings of withdrawal symptoms, given that the dose of 
heroin had not yet been administered. After heroin administration, but not after placebo, we found 
the expected decrease in patients’ craving and withdrawal level. 
The observed plasma concentrations of heroin and its metabolites confirmed the very short half-life 
of heroin and revealed a plateau phase, with relatively stable plasma levels of the active metabolite 
morphine over a prolonged time period after 10 min, underscoring this acute stress suppressive 
effect of heroin, even one hour after administration (32).  
The clinical consequences of this heroin effect on the HPA axis have not been clear. However, it 
has been suggested that ─ in contrast to increased dopamine and opioid peptide function ─ 
increased corticotropin-releasing factor (CRF) and cortisol levels are associated with negative 
affects and stress like-states in drug users (33). Additionally, animal models have shown that acute 
stress induces drug-seeking behavior and drug self-administration after prolonged abstinence, 
indicating the significance of stress-like states for craving and relapse (34). In animals, this stress-
induced reinforcement of drug seeking behavior appears to depend particularly on the activation of 
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CRH levels and the extended amygdala (35). In heroin-dependent patients, the activation of the 
amygdala is followed by a decrease in the activation of different brain areas, including the 
amygdala, after methadone (36) and buprenorphine administration (37).  
We demonstrated a decrease in negative affects such as anxiety after heroin administration. This 
dampening effect of negative affects – including craving and withdrawal level – highlights the acute 
emotional regulation effect of heroin administration and may be a relevant factor in maintaining 
drug-taking behaviour (38). Previous studies have demonstrated the emotional regulation effect of 
methadone application too, but with slightly higher opioid doses (8). Moreover, studies on 
intravenously injected heroin may better reflect the pattern of drug use in heroin addicts. 
Our findings suggest that heroin and other opioids may contribute to the normalization of impaired 
emotional processing and emphasize the benefits of regular opioid substitution for heroin-dependent 
patients (39).  
We conclude that HPA axis activity and negative affects can be significantly suppressed by regular 
opioid administration in heroin-dependent patients, which may also prevent later illegal drug use 
and relapse.  
Our patients were recruited from a population which mainly consisted of individuals with long-
standing polysubstance use. Although this problem is virtually inevitable when chronic heroin-
dependent individuals are examined, it may have biased the results. The findings may thus not 
apply to all groups of heroin users and maintenance patients. We examined the effects of heroin in a 
controlled study design that is only possible in a country that has heroin-assisted treatment 
programs. We did not have a completely balanced study design. However, there was no significant 
influence of the random order of the injected substance in the patient group.  
These limitations notwithstanding, we think our results retain significant clinical implications. They 
establish that heroin suppresses the HPA axis response and may protect stress-sensitive heroin-
dependent patients against their heightened stress response.   
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Table 1: Socio-demographic and diagnostic characteristics of the study sample. Experimental 
group (patients) n = 28, control group (healthy persons) n = 20.  
Measurements 
Mean (SD) 
p-value Experimental 
group 
Control 
group 
Age  41.3 (6.6) 40.3 (10.9) .718 
Male gender (%)  19 (67.9) 14 (70.0) .875 
Partnership (%) 9 (32.1) 15 (75.0) .003 
Employment (%) 11 (39.3) 20 (100.0) .000 
Disability (%) 9 (32.1) 0 (0.0) .005 
Doses of DAM (mg/day)  318.6 (131.7) -  
Methadone maintenance (%) 13 (46.4) -  
Doses of methadone (mg/day) 13.4 (17.4) -  
Duration of dependence (years)   20.8 (6.6) -  
Age at the first-time heroin use (years)  19.0 (3.4) -  
Duration of opioid maintenance (years) 6.7 (4.5) -  
Substance abuse: 
 - tobacco (%) 
 - number of cigarettes/day 
 - cocaine (%) 
 - cannabis (%) 
 
28 (100.0) 
21.0 (9.1) 
15 (53.6) 
8 (28.6) 
 
20 (100.0) 
11.5 (8.2) 
- 
- 
 
1.000 
.001 
 
 
Note: SD = Standard deviation. 
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Table 2: Effects of the interaction between the substance (DAM/placebo) and the 
measurement time on the stress hormone distributions.  
Source SS df MS F p-value 
ACTH 
substance 18191.06 1.00 18191.06 8.75 .007 
substance x group 10378.19 1.00 10378.19 4.99 .034 
error (substance) 54075.96 26.00 2079.85   
time 8727.18 1.28 6822.93 8.64 .003 
time x group 1473.97 2.00 736.99 1.46 .242 
error (time) 26267.26 33.26 789.84   
substance x time 7817.41 1.26 6222.89 8.04 .005 
substance x time x group 187.78 2.00 93.89 0.19 .825 
error (substance x time) 25287.99 32.66 774.23   
Cortisol serum 
substance 273430.98 1.00 273430.98 7.08 .013 
substance x group 264945.12 1.00 264945.12 6.86 .015 
error (substance) 1004903.26 26.00 38650.13   
time 330203.36 1.56 212379.78 29.33 .000 
time x group 24674.72 2.00 12337.36 2.19 .122 
error (time) 292671.56 40.42 7240.01   
substance x time 415104.72 1.41 293797.10 37.33 .000 
substance x time x group 10751.19 2.00 5375.59 0.97 .387 
error (substance x time) 289112.73 36.74 7870.16   
Cortisol saliva 
substance 7912.05 1.00 7912.05 8.14 .008 
substance x group 8016.98 1.00 8016.98 8.25 .008 
error (substance) 25276.02 26.00 972.15   
time 834.43 2.00 417.22 1.00 .376 
time x group 2699.93 2.00 1349.97 3.22 .048 
error (time) 21774.80 52.00 418.75   
substance x time 7662.70 2.00 3831.35 16.99 .000 
substance x time x group 1468.06 2.00 734.03 3.26 .047 
error (substance x time) 11726.02 52.00 225.50   
Note: SS = Sum of Squares; df = degrees of freedom; MS = Mean Square, x = Interaction. 
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Figure 1: Plasma concentrations of diacetylmorphine (DAM) and its metabolites in 
diacetylmorphine (heroin)-maintained patients before and after diacetylmorphine (heroin) 
injection. Means and standard errors are displayed. 
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Figure 2: ACTH concentration in diacetylmorphine (heroin)-maintained patients after 
diacetylmorphine (heroin) or placebo (saline) injection and healthy controls after placebo 
(saline) injection. Means and standard errors are displayed. *** = p < 0.001. 
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Figure 3: Serum cortisol concentration in diacetylmorphine (heroin)-maintained patients after 
diacetylmorphine (heroin) or placebo injection and healthy controls after placebo (saline) 
injection. Means and standard errors are displayed. ** = p < 0.01. 
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Figure 4: Saliva cortisol concentration in diacetylmorphine (heroin)-maintained patients after 
diacetylmorphine (heroin) or placebo injection and healthy controls after placebo (saline) 
injection. Means and standard errors are displayed. *** = p < 0.001. 
 
n.s 
*** 
Substance 
administration 
